Tumor-associated proteases (TAPs), such as legumain, are actively involved in cancer progression; they have been used as biomarkers for diagnosis, prognosis, and drug targeting. As a result, in-vivo detection and traffi cking of TAPs have attracted a great deal of attention. TAP-specifi c probes for in-vivo imaging, however, remain rare. A TAP-responsive hybrid nanoprobe system based on quantum dots (QD) and the fl uorescence resonance energy transfer (FRET) effect is presented for the detection of legumain (asparaginyl endopeptidase), which is overexpressed in many tumors. A novel hybrid construction method is developed for fabricating the nanoprobe, by which the strong heparin-protamine affi nity is used for conjugation. The hybrid comprises two components: 1) low-molecular-weight heparin (LH)-modifi ed QD, and 2) low-molecular-weight protamine (LMWP)-conjugated fl uorescence quencher QSY21, through a legumain-cleavable linker. The hybrid nanoprobe (i.e., a FRET system) is self-assembled via the LH-LMWP affi nity. The linker between LMWP and QSY21 is selectively cleaved by legumain, leading to QSY21 detachment and fl uorescence recovery in the tumor. In-vivo imaging is successfully achieved in the colon tumor mouse model. Importantly, such a hybrid nanoprobe system is adaptable for the detection of other TAPs (e.g., matrix metalloproteinase -2) by using an established, corresponding substrate-peptide linker, thereby offering a universal platform for TAP detection and tumor imaging.
Introduction
Proteases are involved in many biological and pathological processes via the regulatory mechanism of proteolysis, and consequently, they affect disease progression-typically in cancer, such as tumor angiogenesis, invasion, and metastasis. [ 1 ] www.afm-journal.de www.MaterialsViews.com wileyonlinelibrary.com © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim permeation and retention" (EPR) effect. [ 10 ] The peptide linker will then be cleaved by legumain in the tumor, releasing the QSY21 quencher, and rendering the fl uorescence of the recovered QD.
The proposed hybrid probe system offers several major benefi ts. First, conjugation of the donor and acceptor moieties at each end of a cleavable linker typically incurs extra effort and expense, due to the complicated synthesis route and the low yield. The automatic formation of the affi nity-based LH-LP linkage in our hybrid system may be what is needed to ease such synthesis problems. Secondly, the hybrid QD system could serve as a generic platform technique for the development of imaging probes in the detection of various types of TAPs, simply by using a corresponding peptide linker that is specifi cally cleavable by the targeted protease to connect the QSY21 quencher to the LP, the LH binder. Last but not least, the nanoscale effect of the system allows for passive tumor targeting and increased tumor accumulation of the probes via the EPR effect.
In our studies, the hybrid nanoprobe was examined for its legumain-activatable imaging function under various conditions, including those of the cell culture, ex-vivo tumor slices, in-situ tissues, and in-vivo systemic targeted activation in the tumor.
Results and Discussion
The releasable QSY21 quencher was conjugated to the ε-amino group of the lysine of a strategically designed chimeric peptide (sequence: KPTNGGGVSRRRRRRGGRRRR; K: lysine, P: proline, T: threonine, N: asparagine, G: glycine, V: valine, S: serine, R: arginine) comprising a legumain-cleavable substrate and LP; the substrate sequence of PTN can be recognized and specifi cally cleaved by legumain. This conjugate was termed PEP-QSY. Triglycine (GGG), used as a fl exible peptide tether, was incorporated between the legumain-recognizable substrate (KPTN) and the LP (VSRRRRRRGGRRRR) in order to provide increased accessibility to the legumain-cleavable substrate, thereby enhancing the cleavage effi ciency. Via the electrostatic affi nity between LH and LP, the activatable QD-based FRET nanoprobe system (QD-LH/PEP-QSY, further abbreviated to QD/QSY ) was formed. Fluorescence of the QD was signifi cantly inhibited by increasing the amount of the attached quencher of PEP-QSY, and the intensity was reduced to around 10% when the QD/QSY ratio reached 3:1, but with no further reduction in intensity beyond this ratio ( Figure 1 A) . Hence, the ratio of 3:1 was selected for the subsequent investigations. The nanoprobe of QD/QSY was characterized using dynamic light scattering (DLS) and transmission electron microscopy (TEM) (Figure 1 B,C) . As shown in Figure 1 D, the fl uorescence of the nanoprobe remained stable for up to 120 h in both phosphate buffered saline (PBS) and cell culture medium (DMEM, Dulbecco's Modifi ed Eagle's Medium) at 37 °C. The QD-LH and its FRET-based nanoprobe displayed remarkable biocompatibility with cells when using the model non-tumoral 293T cell line; nearly 80% cell viability was observed even at a nanoparticle concentration as high as 1.5 mg/mL in (Figure 1 E) . The fi ndings suggest the safety and potential of the nanoprobe for use in in-vivo studies.
A preliminary activation investigation was conducted by adding protamine to the QD/QSY system. As previously demonstrated by our study of the strategy termed ATTEMPTS (antibody-targeted, triggerable, electrically modifi ed prodrug-type strategy), [ 11 ] protamine has a stronger affi nity to LH than to LP and can thus cause the detachment of PEP-QSY component from the QD/QSY complex. Over 80% recovery of the fl uorescence was achieved after the addition of an adequate amount of protamine to the QD/QSY hybrid nanoprobe ( Figure 2 A,B) , indicating the successful reversal of the deactivated FRET system. Subsequent to this study, enzymatic activation of the nanoprobe by legumain was examined. Fluorescence of the nanoprobe was effi ciently activated following by the addition of legumain (Figure 2 C,D) . In contrast, almost no recovery of the fl uorescence was obtained when a non-specifi c enzyme trypsin was used, due to its inability to cleave away the quencher component (PEP-QSY) from the QD/QSY (Figure 2 E,F) , indicating the specifi city of activation of this system by legumain.
Cellular activation of the QD/QSY system was performed using both the normal HEK 293T cell line and the Adv. Funct. Mater. 2014, 24, 5443-5453 Scheme 1. Activatable nanoprobe comprises two components: 1) QD-LH: the fl uorescence donor; and 2) the FRET quencher QSY21 coupled to a chimeric peptide (PEP) comprising LP and a legumain-cleavable sequence. The two components are linked via a tight but reversible electrostatic binding based on the LH-LP interaction, and thus form a FRET system (QD-LH/PEP-QSY), resulting in fl uorescence quenching. The QSY21 quencher will detach once its linker is cleaved by legumain, and fl uorescence is activated. Figure 4 D. Therefore, it caused slight activation. Moreover, the serum proteases may result in low non-specifi c activation. However, the increase in activation effi ciency in the HEK 293T-Leg cells are very signifi cant compared to that in HEK 293T cells (e.g., 93% versus 25% at a nanoprobe concentration of 80 µg/mL).
The activation process within the cell was further examined by using confocal laser scanning microscopy (CLSM). The initial fl uorescence activation of the nanoprobe apparently occurred on the membrane or in the extracellular space ( Figure 5 A,B); it was then transported into the cell ( Figure 5 C,D) . Interestingly, at the end of the study, the QD fl uorescence was transferred back to the extracellular space again, probably via the cellular event of exocytosis. Our previous observations indicated that a QD could be exocytosed with a half-life of 21 min. [ 12 ] Formation of the active legumain is a pH-dependent multi-step process in the endosome/lysosome system. [ 13 ] The mature legumain present in the cell membrane and released into the extracellular space is believed to control extracellular matrix remodeling. [ 14 ] Our observations provided additional evidence to support the extracellular enzymatic activity monitored by the nanoprobe. The tissue-specifi c activation of the prodrug-type probe was examined ex vivo using tissue cryosectioning slices that included the tumor and major organs collected from the mice harboring the human colon SW620 xenograft tumor with legumain overexpression. The probe concentration was 160 µg/mL. As expected, activation of the quenched nanoprobe thereby yielding fl uorescence occurred within these tumor slices ( Figure 6 ). In contrast, fl uorescence was not observed in the glutaraldehyde-pretreated tumor slices, because of the denaturation of legumain by glutaraldehyde. This further confi rmed the enzyme-related activation process. Moreover, fl uorescence activation was not found in slices of major organs, apparently due to the lack of legumain expression in these tissues. These ex-vivo fi ndings were in good agreement with the in-vitro results, yielding strong support for the selective and specifi c imaging of legumain-presenting tumor tissues by the hybrid nanoprobe.
To examine the nanoprobe system in situ, mice bearing legumain-overexpressed colon SW620 xenograft tumor were used to study the activation event. As displayed in Figure 7 A and B, the fl uorescence intensity peaked 11 min after peritumoral injection of the probe, with the ROI (region of interest) value of 2.267 × 10 6 , clearly defi ning the target from its surroundings. However, the back (or spine) also displayed fl uorescence signals after 11 min. Because it is at the higher position and is closer to the light source and charge-coupled device (CCD) camera compared to other organs or tissues, it usually causes the increased refraction of light and the strengthened signals, particularly when using the fl uorescence probe with emission wavelength less than 700 nm. Moreover, in order to evaluate the effect of non-specifi c in-vivo activation, the probe was administered via intramuscular injection through the left thigh to the same animal at the 24-min mark after the animal receiving peritumoral administration. As shown in www.afm-journal.de www.MaterialsViews.com wileyonlinelibrary.commerely a slight activation was detected, estimated from the peak fl uorescence intensity at the muscle injection site. The results further confi rmed that activation of the FRET-based nanoprobe could primarily be activated specifi cally at the tumor site, due to the presence of the overexpressed legumain.
To examine the practical feasibility and applicability of the nanoprobe for in-vivo imaging and legumain-detection, quenched nanoprobe was administered through the conventional tail-vein route. Under such conditions, the preferential tumor accumulation of the nanoprobe could be obtained by taking the advantage of the tumor-associated EPR effect. As revealed in Figure 8 A, the fl uorescence intensity in the tumor signifi cantly increased with time-from 0.5 to 2 h; it then plateaued until the 24-h mark, clearly distinguishing the tumor from other tissues. Normalized fl uorescence intensity showed that the fl uorescence signal in the tumor 24 h after i.v. injection was 1.62 times stronger than that at 0.5 h (Figure 8 B) . The major organs were collected 24 h after i.v. injection to better monitor tissue-specifi c activation of the nanoprobe. The normalized fl uorescence intensity showed that the signal in the ex-vivo tumor was 6.0, 2.3, 4.7, 3.4, 5.8, and 4.9 times stronger than that in the heart, liver, spleen, kidney, and brain, respectively (Figure 8 C,D) . It should be pointed out that the fl uorescence distribution in the normal organs was mainly caused by the metabolic degradation of the peptide-based quencher and non-specifi c cleavage of the linker, thereby contributing to mild non-specifi c activation. Taken together, these results further demonstrate the potential and in-vivo applicability of the QD/QSY nanoprobe in the selective detection of legumainpresenting tumors by responding to the legumain-rich tumor microenvironments.
A primary benefi t of this QD/QSY nanoprobe system lies in the universal applicability of the established hybrid construction method. This method possesses great versatility and utility ( Figure 9 ). With this in mind, the presented adaptable strategy could lead to the development of a new paradigm of specially tailored QD-based imaging platforms for tumors carrying specifi c, overexpressed protease biomarkers. The general mechanism for protease-activatable probe design is a FRET effect that is achieved by employing a substrate-peptide as a cleavable linker between the FRET fl uorophore and quencher. To enhance peptide stability and reduce non-specifi c cleavage in vivo, the costly D -forms of peptide sequences are necessary to ensure image quality, especially in those cases involving long peptides (e.g., hairpin structure). [ 15 ] However, although natural amino acids are used in our system, non-specifi c activation was insignifi cant, indicating the additional benefi ts of our strategy.
Conclusion
In summary, we report the development of a novel, proteaseresponsive QD nanoprobe platform for detecting tumor-associated protease biomarkers and for tumor imaging. Molecular imaging of legumain was successfully achieved under cellular, exvivo tissue-slice, in-situ, and in-vivo conditions, providing a promising tool for cancer detection. Importantly, based on the adaptability of this hybrid nanoprobe construction technology, it is envisioned that this imaging system could be applied universally to monitor tumors with known specifi cally overexpressed TAPs, simply by using the corresponding protease-substrate peptide that serves as a linker between LMWP and the fl uorescence quencher. Unlike the conventional probes that typically need to be custom-made for each targeted, specifi c protease, the LHmodifi ed QD serves as a universal fl uorescent moiety. The LH-LMWP-based affi nity linkage provides great convenience for the hybrid construction, easing the fabrication process. This is a versatile method for the fabrication of a protease-activatable probe for in-vivo detection and tumor imaging.
Experimental Section
Materials : NaBH 4 , Tellurium powder, CdCl 2 , NaIO 4 , and cysteamine hydrochloride were obtained from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). MPA was obtained from Alfa Aesar (UK). LH (Enoxaparin Sodium) was obtained from Changshan Biochemical Pharmaceutical Co., Ltd (Shijiazhuang, China). GelRed was purchased from Biotium (Hayward, USA). Fetal bovine serum (FBS), DMEM, penicillin-streptomycin, 0.25% trypsin-EDTA solution (EDTA = ethylenediaminetetra-acetic acid), dimethyl sulfoxide (DMSO), QSY21-NHS (where NHS is N -hydroxysuccinimide), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were obtained from Invitrogen (USA). The Micro BCA protein assay kit and trypan blue were acquired from the Beyotime Institute of Biotechnology (Haimen, China). All other reagents were of analytical grade.
Preparation of the Prodrug-Type Probe : 1) MPA-Coated CdTe Quantum Dots ( QD-MPA): Tellurium powder (0.2 mmol) and NaBH 4 (1.3 mmol) were heated at 80 °C for 1 h under the protection of N 2 in order to prepare the NaHTe solution. A CdCl 2 solution (0.2 mmol) and a MPA solution (0.34 mmol) were mixed togetherb and the pH was adjusted to 12. The NaHTe solution (0.02 mmol) was added to the Cd precursor solution at a reaction ratio of 1:1.7:0.1 (Cd:MPA:Te). The reaction Figure 6 . Ex-vivo detection of the tumor-specifi c nanoprobe activation. Images presented are bright-fi eld, red fl uorescence (QD), blue fl uorescence (DAPI), and merged (Overlap) images. The FRET-based nanoprobe was activated in legumain-presenting tumor tissue (cryosection slide), but it was not activated in the legumain-denatured tumor that was pretreated with glutaraldehyde nor in other normal tissues that did not express legumain.
www.afm-journal.de www.MaterialsViews.com wileyonlinelibrary.commixture was then heated to refl ux under N 2 fl ow. The thus-formed CdTe QDs were purifi ed by precipitation using isopropanol, followed by vacuum drying. Preparation of the Prodrug-Type Probe : 2) Thiol LH (LH-SH): LH (50 mg) was oxidized by sodium periodate in 10 mL of citric acid buffer (0.1 M , pH 7.0) at a molar ratio of 1:1.5 (NaIO 4 :(LH repeating unit)). After purifi cation by dialysis, the product was reacted with cysteamine hydrochloride (11 mg) in 20 mL of phosphate buffer (0.1 M , pH 7.0). Thiol LH was obtained after reduction using sodium borohydride (125 mg) and purifi cation by dialysis.
Preparation of the Prodrug-Type Probe : 3) Ligand-Exchange Reaction from QD-MPA to QD-LH: The LH-SH was added to the QD-MPA solution in PBS (pH 7.4), and incubated overnight at room temperature. The resultant QD-LH was purifi ed by precipitation using isopropanol, followed by vacuum drying.
Preparation of the Prodrug-Type Probe : 4) Coupling of QSY21 to PEP: The chimeric peptide of LP and the legumain-cleavable substrate was synthesized via a solid-state method (sequence: KPTNGGGVSRRRRRRGGRRRR, with N-terminal acetylated and C-terminal amidated, as denoted PEP). PEP in DMSO (10 μg/mL), via the ε-amino group on the terminal lysine, was reacted with the QSY21-NHS ester (1.3:1 mol/mol) in the presence of 1% N -methylmorpholine for 48 h. The product of QSY21-PEP (or PEP-QSY) was determined and purifi ed using reverse-phase C18 high-performance liquid chromatography (HPLC). For quantitative analysis of PEP-QSY, the HPLC conditions were: analytic HPLC system (Agilent-1200, USA) with a C18 column (4.6 mm × 250 mm, 5 μm); λ = 210 nm; fl ow rate of 1 mL/min; gradient elution using H 2 O/(0.1% trifl uoroacetic acid (TFA)) and CH 3 CN/(0.1% TFA) as solvent A and B, and running from (95% A/5% B) to (30% A/70% B) in 30 min. The purifi cation of PEP-QSY was performed by a preparative HPLC (Waters 1525 system, USA) with a C18 column (10 mm × 150 mm, 5 μm). Chromatographic conditions were as follows: λ = 280 nm; fl ow rate of 5 mL/min; gradient elution using H 2 O/(0.1% TFA) and CH 3 CN/(0.1% TFA) as solvent A and B, respectively, and running from (95% A/5% B) to (25% A/75%B) in 10 min.
Preparation of the Prodrug-Type Probe : 5) Self-Assembly of PEP-QSY with QD-LH ( QD/QSY ): The self-assembly of PEP-QSY with QD-LH nanoparticles was prepared by mixing PEP-QSY, in a range of 0−32 μg, with QD-LH (32 μg) in deionized water. The mixtures were incubated for 30 min at room temperature. The FRET effi ciency related to the addition of the quencher (PEP-QSY) was monitored by measuring the fl uorescence intensity using a fl uorospectrometer (Hitachi F4600, Japan).
Characterization of the Prodrug-Type Probe : The sulfhydryl content of the LH-SH was measured using Ellman's reagent, according to the manufacturer's protocol (Thermo Scientifi c Piercer, USA).
Size analysis and the ξ potential of QD-LH were performed using a Zetasizer Nano-ZS90 (Malvern Instrument). The morphology was observed using TEM at an accelerating voltage of 100 kV (JEOL JEM-1200EX, Japan). Fluorescence intensity was measured on a fl uorospectrometer (Hitachi, F4600, Japan).
Preliminary activation of the prodrug-type probe was carried out by adding protamine to competitively substitute the PEP-QSY and thus release QD-LH from the original self-assembly; fl uorescence intensity was measured using the fl uorospectrometer. Colloidal stability of QD-LH and QD/QSY was evaluated in both physiological PBS buffer and cell culture medium at 37 °C for up to 120 h; the fl uorescence intensity was measured using the fl uorospectrometer.
Cell Culture : Human embryonic kidney 293T cells were incubated in DMEM containing 10% FBS and 1% antibiotics at 37 °C in a humidifi ed atmosphere and 5% CO 2 .
In-Vitro Cytotoxicity Assay of the Prodrug-Type Probe: The cytotoxicity was studied in the non-tumoral cell line of 293T. Cells were treated with a series of concentrations of the prodrug-type probe in 96-well plates with a standard MTT procedure. Absorbance was measured at 570 nm using a microplate reader (Thermo, USA). The cell viability was calculated according to the following equation, based on the optical densities of the sample, DMSO, and the control: Cellular Activation of the Prodrug-Type Probe : Cell-specifi c activation of the prodrug-type QD performed in the normal 293T cells and transfected 293T-Leg cells. The QD/QSY was incubated with cells for 5 h. Cells were then washed with PBS three times and fi xed with 4% paraformaldehyde. Extracellular fl uorescence was quenched using trypan blue. Cells were observed using a fl uorescence microscope (Olympus, Japan). Furthermore, the uptake effi ciency was quantitatively measured by FACS. In brief, normal 293T cells and transfected 293T-Leg cells were exposed to the medium containing the prodrug-type probe for 5 h. After washing with PBS, the cells were collected, and further washed with PBS three times. The cells were subjected to fl uorescence analysis with FACS (BD, USA).
In-Vivo Animal Studies : Female BALB/c nude mice (4-5 weeks old, 18-22 g) were housed under specifi c pathogen-free conditions and in a 12 h light/dark cycle. Animals possessed free access to sterilized food pellets and distilled water. The experimental procedures were approved by the Institutional Animal Care and Use Committee.
Xenograft Tumor Mouse Models : Human colon cancer SW620 cells were incubated in RMPI 1640 medium containing 10% FBS, and 1% antibiotics at 37 °C under a humidifi ed atmosphere and 5% CO 2 . A xenograft tumor model was established by inoculating 1 × 10 6 SW620 cells subcutaneously into the back of nude mice.
Tissue-Specifi c Activatio n : Mice were humanely killed and the major organs (heart, liver, spleen, lung, kidney, and tumor) collected for cryosectioning. The tissue slices were divided into two experimental groups: the non-treatment slices, and the enzyme-inactivated slices that were pretreated with 4% glutaraldehyde to denature legumain. The slides were exposed to the prodrug-type nanoprobe (160 μg/mL) for 30 min at room temperature, and then the activated fl uorescence was imaged with a fl uorescence microscope (Olympus, Japan).
In-Vivo Imaging : The mice bearing the SW620 tumor were given the prodrug-type QD via peritumoral or intramuscular injection for in-situ activation and imaging studies. Fluorescent imaging of the QD that was activated by legumain was obtained using the IVIS imaging system (Caliper Life Science) and analyzed using Living Image (Caliper Life Sciences). Furthermore, tail vein intravenous injection was conducted for investigating the application in real-time tumor imaging.
Statistical Analysis : The quantitative data were expressed as mean ± standard deviation (S.D.). Statistical analysis was performed by the Student's t -test. Statistical signifi cance was inferred at a value of P < 0.05. 
